MDC Connects 2024: Webinar 5/5

Commercialising Innovation Dr Rob Grundy CEO Intelligent OMICS

Intelligent OMICS Public and private transcriptomic data sets analysed by a suite of AI tools: Intellomx Distiller

Identification of key genes

Intellomx Driver

Identification of key disease drivers

Intellomx Miner

Defining the disease pathway

Value Proposition: Deploying AI and ML to extract biological knowledge from OMICS data Identifying causal drivers of disease and expediting the biomarker and drug discovery processes.

Business Model: 1.

Intellomx Digital Twin

Anticipate Tox Liabilities

Intellomx Precise

Panel optimization for diagnostics

2.

3.

Technology Driven Consultancy Service model Downstream Drug Discovery Value Generate IP of value by exploiting biological knowledge - Licensing

Be driven by the problem…

Position any innovation in the context of an existing well understood industry challenge: • Therapeutic Class e.g. Oncology, Fibrotic Disease, Neuroscience • Platform Need e.g ADCs, Protein-protein interactions • Development Bottle Neck e.g. Patient recruitment technologies, Advanced therapies manufacturing Confirm these challenges through customer discovery

Articulate your solution in the context of problem…

Problem: Drug Development is rife with expense and time consuming failure.

Solution: Intellomx allows partners to better understand disease biology without the bias of previous literature and select causal, stable targets present across a disease population.

The commercialization conundrum…

• Intellomx has the ability to provide a service and generate IP • Long term value vs short term viability • Solution….do both strategically • Near term revenue generating fee for service • Long term value generation through collaborative research

Route to Market • Marketing channels & strategy • Who is the buyer • BD or sales?

• Recurring service or one-off deal?

• Licensing model?

Working with J&J… Deal source: Email Circular and InPart • Integration into biology and data science teams • Exposure to wider R&D organisation • JLABS membership • CEO roundtables • Community membership • Industry validation

Causal disease modelling of Sjogren’s Disease

Working with Servier Deal Source: Email Circular • Integration into biology and data science teams • Exposure to wider R&D organisation – subsequent project extension into Neuroscience TA • Refinement of methodology • Publication submission

Learnings…

• Speak to a clear problem • Identify a champion with need and budget • Build upon relationships to extend commercial partnerships • DELIVER!

Contact : Rob Grundy, CEO: rob.grundy@intellomx.com +44 7976 600016